Failure to Satisfy Listing Rule (Form 8-K)

Nasdaq Corporate Governance Standard Non-Compliance

On March 17, 2026, Lifeward Ltd. (the "Company") received a notice (the "Audit Committee Notice") from the Nasdaq Listing Qualifications Department indicating that, following Hadar Levy's resignation from the Board of Directors of the Company, which reduced the Audit Committee to two members, the Company no longer complies with the audit committee requirement under Nasdaq Listing Rule 5605(c)(2)(A), which requires listed companies to have an audit committee of at least three members.

The Company is in the process of reviewing and evaluating potential options to regain compliance with these continued listing requirements noted above in a manner consistent with the cure period set out in Nasdaq Listing Rule 5605(c)(4) of the Nasdaq rules. Such cure period provide that the Company will have until the earlier of its next annual meeting of shareholders or February 24, 2027; provided, however, that if the Company's next annual meeting of shareholders is held before August 24, 2026, then the Company must evidence compliance no later than August 24, 2026. There can be no assurance that the Company will successfully regain compliance with these continued listing requirements within the applicable cure period.

The Audit Committee Notice does not have an immediate effect on the listing of the Company's ordinary shares, and the ordinary shares will continue to trade on The Nasdaq Capital Market under the symbol "LFWD" at this time.